New

Cutaneous Fibrosis Treatment Market

2021

Cutaneous Fibrosis Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Keloid, Scleroderma, Radiation-induced Cutaneous Fibrosis, GvHD Associated Cutaneous Fibrosis); Route of Administration (Oral, Injectable, Topical); End User (Hospitals, Clinics, Others) and Geography

| Report Code: TIPRE00016848 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Cutaneous Fibrosis Treatment Market 2028 By Indication, Route of Administration, End User and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Cutaneous fibrosis is characterized by the persistent accumulation of collagen and other extracellular matrix (ECM) molecules under the skin. Cutaneous fibrosis forms an integral component of various skin diseases, including hypertrophic scar, scleroderma, and keloids. These diseases lead to dysregulation of connective tissue metabolism through the activation of the dermal fibroblasts. Corticosteroids, immunotherapy drugs, immunoglobulins, and anti-fibrotic drugs are commonly used to treat cutaneous fibrosis and associated skin diseases.

MARKET DYNAMICS

The cutaneous fibrosis treatment market has shown a significant evolution over the forecast period. The key driving factors include the increasing incidence of cutaneous fibrosis-associated conditions, like scleroderma, Graft Versus Host Disease (GVHD),keloids (severe form) and other conditions. Scleroderma and other cutaneous fibrosis-associated diseases are more prevalent in persons aged above 35 to 40 years. The aging population worldwide, especially in the developed regions, is expected to boost the prevalence of cutaneous fibrosis-associated indications, thereby increasing the prevalence of cutaneous fibrosis. The aging population is growing at a faster rate in developing countries compared to developed countries. For example, France took over 115 years to transform into an aging society, whereas China is estimated to take only 25 years for a similar transition. Besides, the prevalence of keloid scars related to physical injuries is also expected to increase with many surgeries, road accidents, and trauma injuries. However, cutaneous fibrosis generally affects people suffering from diseases such as keloids, GvHD, scleroderma, radiation therapies. Cutaneous fibrosis is a rare disease. Limited awareness among healthcare professionals and the general population delays the diagnosis and treatment of cutaneous fibrosis, thus hampering the market growth.

MARKET SCOPE

The "Cutaneous Fibrosis Treatment Market Analysis to 2028" is a specialized and in-depth study of pharmaceuticalsin the healthcare industry, focusing on the global market trend analysis. This reportoffers an outline of the cutaneous fribrosis treatment marketwith detailed market segmentation by disease indication, route of administration, and end-user. The cutaneous fribrosis treatment marketis expected to witness high rise during the forecast period. The report focuses on the vital statistics on the market status of the leading players in the cutaneous fribrosis treatment marketand offers key trends and opportunities.

MARKET SEGMENTATION

The market is segmented based on indication, route of administration, and end-user. Based on indication, the market is categorized as keloid, scleroderma, radiation-induced cutaneous fibrosis, GvHD associated cutaneous fibrosis.Based onthe route of administration, the market is segmented asoral, injectable, and topical. Based on the end-user, the market is segmented ashospitals, clinics, and others.

REGIONAL FRAMEWORK

The report lays out a comprehensive outline of the industry, including both quantitative and qualitative information. The report gives a sketch and forecast of the cutaneous fribrosis treatment marketbased onvarious segments.It also consistsof market size and forecast estimates from the year 2020 to2028 concerning five major regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The marketby each region is then subdivided into respective countries and segments. The report comprises the analysis and forecast of eighteen countries globally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the cutaneous fribrosis treatment marketfrom both the demand and supply side. Moreover, it evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends.
The report also consistsof precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the cutaneous fribrosis treatment marketin these regions.



Get more information on this report :

MARKET PLAYERS


The report contains critical developments in the cutaneous fribrosis treatment marketas organic and inorganic growth strategies. Various enterprisesfocuson organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed in the market were acquisitions and partnerships & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market players from the cutaneous fribrosis treatment marketare anticipated to have profitable growth opportunities in the coming years with the rising demand for the cutaneous fribrosis treatment market globally. Given below is the list of few companies engaged in the cutaneous fribrosis treatment market.

The report also consists of the profiles of key players in the cutaneous fribrosis treatment market, along with their SWOT analysis and market strategies. Additionally, the report elaborates on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.

  •  Gilead Sciences, Inc.
  •  Novartis AG
  •  F. Hoffmann-La Roche Ltd
  •  Teva Pharmaceutical Industries Ltd
  •  AstraZeneca
  •  Bayer AG
  •  Bristol-Myers Squibb
  •  Sanofi
  •  Genentech
  •  BoehringerIngelheim International GmbH

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and provides various customization options in the current study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Cutaneous Fibrosis Treatment Market - By Indication
1.3.2 Cutaneous Fibrosis Treatment Market - By Route of Administration
1.3.3 Cutaneous Fibrosis Treatment Market - By End User
1.3.4 Cutaneous Fibrosis Treatment Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. CUTANEOUS FIBROSIS TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. CUTANEOUS FIBROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. CUTANEOUS FIBROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. CUTANEOUS FIBROSIS TREATMENT - GLOBAL MARKET OVERVIEW
6.2. CUTANEOUS FIBROSIS TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. CUTANEOUS FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. KELOID
7.3.1. Overview
7.3.2. Keloid Market Forecast and Analysis
7.4. SCLERODERMA
7.4.1. Overview
7.4.2. Scleroderma Market Forecast and Analysis
7.5. RADIATION-INDUCED CUTANEOUS FIBROSIS
7.5.1. Overview
7.5.2. Radiation-induced Cutaneous Fibrosis Market Forecast and Analysis
7.6. GVHD ASSOCIATED CUTANEOUS FIBROSIS
7.6.1. Overview
7.6.2. GvHD Associated Cutaneous Fibrosis Market Forecast and Analysis
8. CUTANEOUS FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. INJECTABLE
8.4.1. Overview
8.4.2. Injectable Market Forecast and Analysis
8.5. TOPICAL
8.5.1. Overview
8.5.2. Topical Market Forecast and Analysis
9. CUTANEOUS FIBROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis

10. CUTANEOUS FIBROSIS TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Cutaneous Fibrosis Treatment Market Overview
10.1.2 North America Cutaneous Fibrosis Treatment Market Forecasts and Analysis
10.1.3 North America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Indication
10.1.4 North America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Cutaneous Fibrosis Treatment Market
10.1.6.1.1 United States Cutaneous Fibrosis Treatment Market by Indication
10.1.6.1.2 United States Cutaneous Fibrosis Treatment Market by Route of Administration
10.1.6.1.3 United States Cutaneous Fibrosis Treatment Market by End User
10.1.6.2 Canada Cutaneous Fibrosis Treatment Market
10.1.6.2.1 Canada Cutaneous Fibrosis Treatment Market by Indication
10.1.6.2.2 Canada Cutaneous Fibrosis Treatment Market by Route of Administration
10.1.6.2.3 Canada Cutaneous Fibrosis Treatment Market by End User
10.1.6.3 Mexico Cutaneous Fibrosis Treatment Market
10.1.6.3.1 Mexico Cutaneous Fibrosis Treatment Market by Indication
10.1.6.3.2 Mexico Cutaneous Fibrosis Treatment Market by Route of Administration
10.1.6.3.3 Mexico Cutaneous Fibrosis Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Cutaneous Fibrosis Treatment Market Overview
10.2.2 Europe Cutaneous Fibrosis Treatment Market Forecasts and Analysis
10.2.3 Europe Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Indication
10.2.4 Europe Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Cutaneous Fibrosis Treatment Market
10.2.6.1.1 Germany Cutaneous Fibrosis Treatment Market by Indication
10.2.6.1.2 Germany Cutaneous Fibrosis Treatment Market by Route of Administration
10.2.6.1.3 Germany Cutaneous Fibrosis Treatment Market by End User
10.2.6.2 France Cutaneous Fibrosis Treatment Market
10.2.6.2.1 France Cutaneous Fibrosis Treatment Market by Indication
10.2.6.2.2 France Cutaneous Fibrosis Treatment Market by Route of Administration
10.2.6.2.3 France Cutaneous Fibrosis Treatment Market by End User
10.2.6.3 Italy Cutaneous Fibrosis Treatment Market
10.2.6.3.1 Italy Cutaneous Fibrosis Treatment Market by Indication
10.2.6.3.2 Italy Cutaneous Fibrosis Treatment Market by Route of Administration
10.2.6.3.3 Italy Cutaneous Fibrosis Treatment Market by End User
10.2.6.4 Spain Cutaneous Fibrosis Treatment Market
10.2.6.4.1 Spain Cutaneous Fibrosis Treatment Market by Indication
10.2.6.4.2 Spain Cutaneous Fibrosis Treatment Market by Route of Administration
10.2.6.4.3 Spain Cutaneous Fibrosis Treatment Market by End User
10.2.6.5 United Kingdom Cutaneous Fibrosis Treatment Market
10.2.6.5.1 United Kingdom Cutaneous Fibrosis Treatment Market by Indication
10.2.6.5.2 United Kingdom Cutaneous Fibrosis Treatment Market by Route of Administration
10.2.6.5.3 United Kingdom Cutaneous Fibrosis Treatment Market by End User
10.2.6.6 Rest of Europe Cutaneous Fibrosis Treatment Market
10.2.6.6.1 Rest of Europe Cutaneous Fibrosis Treatment Market by Indication
10.2.6.6.2 Rest of Europe Cutaneous Fibrosis Treatment Market by Route of Administration
10.2.6.6.3 Rest of Europe Cutaneous Fibrosis Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Cutaneous Fibrosis Treatment Market Overview
10.3.2 Asia-Pacific Cutaneous Fibrosis Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Indication
10.3.4 Asia-Pacific Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Cutaneous Fibrosis Treatment Market
10.3.6.1.1 Australia Cutaneous Fibrosis Treatment Market by Indication
10.3.6.1.2 Australia Cutaneous Fibrosis Treatment Market by Route of Administration
10.3.6.1.3 Australia Cutaneous Fibrosis Treatment Market by End User
10.3.6.2 China Cutaneous Fibrosis Treatment Market
10.3.6.2.1 China Cutaneous Fibrosis Treatment Market by Indication
10.3.6.2.2 China Cutaneous Fibrosis Treatment Market by Route of Administration
10.3.6.2.3 China Cutaneous Fibrosis Treatment Market by End User
10.3.6.3 India Cutaneous Fibrosis Treatment Market
10.3.6.3.1 India Cutaneous Fibrosis Treatment Market by Indication
10.3.6.3.2 India Cutaneous Fibrosis Treatment Market by Route of Administration
10.3.6.3.3 India Cutaneous Fibrosis Treatment Market by End User
10.3.6.4 Japan Cutaneous Fibrosis Treatment Market
10.3.6.4.1 Japan Cutaneous Fibrosis Treatment Market by Indication
10.3.6.4.2 Japan Cutaneous Fibrosis Treatment Market by Route of Administration
10.3.6.4.3 Japan Cutaneous Fibrosis Treatment Market by End User
10.3.6.5 South Korea Cutaneous Fibrosis Treatment Market
10.3.6.5.1 South Korea Cutaneous Fibrosis Treatment Market by Indication
10.3.6.5.2 South Korea Cutaneous Fibrosis Treatment Market by Route of Administration
10.3.6.5.3 South Korea Cutaneous Fibrosis Treatment Market by End User
10.3.6.6 Rest of Asia-Pacific Cutaneous Fibrosis Treatment Market
10.3.6.6.1 Rest of Asia-Pacific Cutaneous Fibrosis Treatment Market by Indication
10.3.6.6.2 Rest of Asia-Pacific Cutaneous Fibrosis Treatment Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Cutaneous Fibrosis Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Cutaneous Fibrosis Treatment Market Overview
10.4.2 Middle East and Africa Cutaneous Fibrosis Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Indication
10.4.4 Middle East and Africa Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Cutaneous Fibrosis Treatment Market
10.4.6.1.1 South Africa Cutaneous Fibrosis Treatment Market by Indication
10.4.6.1.2 South Africa Cutaneous Fibrosis Treatment Market by Route of Administration
10.4.6.1.3 South Africa Cutaneous Fibrosis Treatment Market by End User
10.4.6.2 Saudi Arabia Cutaneous Fibrosis Treatment Market
10.4.6.2.1 Saudi Arabia Cutaneous Fibrosis Treatment Market by Indication
10.4.6.2.2 Saudi Arabia Cutaneous Fibrosis Treatment Market by Route of Administration
10.4.6.2.3 Saudi Arabia Cutaneous Fibrosis Treatment Market by End User
10.4.6.3 U.A.E Cutaneous Fibrosis Treatment Market
10.4.6.3.1 U.A.E Cutaneous Fibrosis Treatment Market by Indication
10.4.6.3.2 U.A.E Cutaneous Fibrosis Treatment Market by Route of Administration
10.4.6.3.3 U.A.E Cutaneous Fibrosis Treatment Market by End User
10.4.6.4 Rest of Middle East and Africa Cutaneous Fibrosis Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Cutaneous Fibrosis Treatment Market by Indication
10.4.6.4.2 Rest of Middle East and Africa Cutaneous Fibrosis Treatment Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Cutaneous Fibrosis Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Cutaneous Fibrosis Treatment Market Overview
10.5.2 South and Central America Cutaneous Fibrosis Treatment Market Forecasts and Analysis
10.5.3 South and Central America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Indication
10.5.4 South and Central America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Cutaneous Fibrosis Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Cutaneous Fibrosis Treatment Market
10.5.6.1.1 Brazil Cutaneous Fibrosis Treatment Market by Indication
10.5.6.1.2 Brazil Cutaneous Fibrosis Treatment Market by Route of Administration
10.5.6.1.3 Brazil Cutaneous Fibrosis Treatment Market by End User
10.5.6.2 Argentina Cutaneous Fibrosis Treatment Market
10.5.6.2.1 Argentina Cutaneous Fibrosis Treatment Market by Indication
10.5.6.2.2 Argentina Cutaneous Fibrosis Treatment Market by Route of Administration
10.5.6.2.3 Argentina Cutaneous Fibrosis Treatment Market by End User
10.5.6.3 Rest of South and Central America Cutaneous Fibrosis Treatment Market
10.5.6.3.1 Rest of South and Central America Cutaneous Fibrosis Treatment Market by Indication
10.5.6.3.2 Rest of South and Central America Cutaneous Fibrosis Treatment Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Cutaneous Fibrosis Treatment Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. CUTANEOUS FIBROSIS TREATMENT MARKET, KEY COMPANY PROFILES
12.1. GILEAD SCIENCES, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. F. HOFFMANN-LA ROCHE LTD
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ASTRAZENECA
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. BAYER AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SANOFI
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. GLAXOSMITHKLINE PLC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Gilead Sciences, Inc.
2. Novartis AG
3. F. Hoffmann-La Roche Ltd
4. Teva Pharmaceutical Industries Ltd
5. AstraZeneca
6. Bayer AG
7. Bristol-Myers Squibb
8. Sanofi
9. GlaxoSmithKline plc.
10. Boehringer Ingelheim International GmbH
TIPRE00016848
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.